8HZ8 image
Deposition Date 2023-01-08
Release Date 2024-03-13
Last Version Date 2024-10-30
Entry Detail
PDB ID:
8HZ8
Keywords:
Title:
Structure of PPIA in complex with the peptide of NRF2
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.81 Å
R-Value Free:
0.24
R-Value Work:
0.23
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Peptidyl-prolyl cis-trans isomerase A, N-terminally processed
Gene (Uniprot):PPIA
Chain IDs:A
Chain Length:164
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:NRF2 peptide
Chain IDs:B (auth: C)
Chain Length:4
Number of Molecules:1
Biological Source:synthetic construct
Primary Citation
PPIA dictates NRF2 stability to promote lung cancer progression.
Nat Commun 15 4703 4703 (2024)
PMID: 38830868 DOI: 10.1038/s41467-024-48364-4

Abstact

Nuclear factor erythroid 2-related factor 2 (NRF2) hyperactivation has been established as an oncogenic driver in a variety of human cancers, including non-small cell lung cancer (NSCLC). However, despite massive efforts, no specific therapy is currently available to target NRF2 hyperactivation. Here, we identify peptidylprolyl isomerase A (PPIA) is required for NRF2 protein stability. Ablation of PPIA promotes NRF2 protein degradation and blocks NRF2-driven growth in NSCLC cells. Mechanistically, PPIA physically binds to NRF2 and blocks the access of ubiquitin/Kelch Like ECH Associated Protein 1 (KEAP1) to NRF2, thus preventing ubiquitin-mediated degradation. Our X-ray co-crystal structure reveals that PPIA directly interacts with a NRF2 interdomain linker via a trans-proline 174-harboring hydrophobic sequence. We further demonstrate that an FDA-approved drug, cyclosporin A (CsA), impairs the interaction of NRF2 with PPIA, inducing NRF2 ubiquitination and degradation. Interestingly, CsA interrupts glutamine metabolism mediated by the NRF2/KLF5/SLC1A5 pathway, consequently suppressing the growth of NRF2-hyperactivated NSCLC cells. CsA and a glutaminase inhibitor combination therapy significantly retard tumor progression in NSCLC patient-derived xenograft (PDX) models with NRF2 hyperactivation. Our study demonstrates that targeting NRF2 protein stability is an actionable therapeutic approach to treat NRF2-hyperactivated NSCLC.

Legend

Protein

Chemical

Disease

Primary Citation of related structures